Received Feb 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | D4774 | — |
the administration of 2 doses of Twinrix at less than the recommended interval.; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 60-year-old male patient who received HAB (Twinrix) (batch number D4774, expiry date 12-SEP-2025) for prophylaxis. Concomitant products included HEPATITIS A VACCINE INACT;HEPATITIS B VACCINE RHBSAG (YEAST) (TWINRIX). On 15-OCT-2024, the patient received the 2nd dose of Twinrix. On 15-OCT-2024, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too short (Verbatim: the administration of 2 doses of Twinrix at less than the recommended interval.). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 30-JAN-2025 The reporter request data about the administration of 2 doses of Twinrix at less than the recommended interval which led to drug dose administration interval too short. The provided data about vaccine, patient and even, consenting to receive follow-up. Vaccine administration facility was the same as primary reporter.